読み込み中
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
前日終値
$1.18
−$0.03 · -2.48%
市場前
$1.18
$0.00 · 0.00%
10月12日 6:18 ET
日中の時刻はETです。市場データは遅延する場合があります。
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
日中レンジ
現在 $1.18
52週レンジ
現在 $1.18
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
65
割安
センチメント
56
まちまち
リスク
81
極めて高いリスク
モメンタム
17
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
日中レンジ
現在 $1.18
52週レンジ
現在 $1.18
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 131.1万 USD | 65.8万 USD | — | — | — |
| 売上原価 | 396.3万 USD | 123.8万 USD | — | — | 74.76万 USD |
| 粗利益 | −265.2万 USD | −58万 USD | — | — | −74.76万 USD |
| 研究開発 | 236.9万 USD | 553.2万 USD | 521万 USD | 576.5万 USD | 262.37万 USD |
| 販売・一般管理 | 252.1万 USD | 252.6万 USD | 450.5万 USD | 529.6万 USD | 742.36万 USD |
| 営業費用 | 489万 USD | 805.8万 USD | 970.6万 USD | 1106.1万 USD | 1004.73万 USD |
| 受取利息 | 2万 USD | 10.05万 USD | 392.4万 USD | 305.1万 USD | 928.76 USD |
| 支払利息 | 35.9万 USD | 143.88万 USD | 380.1万 USD | — | 336.36万 USD |
| 減価償却費と償却費 | 142.1万 USD | 164.9万 USD | 51.4万 USD | 56.2万 USD | 47.1万 USD |
| 営業利益 | −754.2万 USD | −863.8万 USD | −970.6万 USD | −1106.1万 USD | −1079.49万 USD |
| 純利益 | −830.7万 USD | 479.6万 USD | −650万 USD | −579.6万 USD | −1237.66万 USD |
会社概要が更新されました 2026年10月12日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
